We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Challenges & Solutions in Today's In Vitro Transporter Research Landscape

Video   Sep 03, 2018

 

Webinar Aired: 6/20/2018 Presenter: Joanna Barbara, Ph.D., Sekisui XenoTech Vice President of Scientific Operations Key concepts discussed in this webinar included: - Ramifications of recent FDA in vitro DDI guidance changes to transporter study designs - Challenges from diverse compounds in otherwise straightforward assays - Solutions to problems associated with specific compound characteristics - Case studies of problematic observations or data and the creative methods of troubleshooting applied Synopsis: In vitro drug transporter inhibition and substrate potential assays as well as general cell permeability studies are performed at various stages of drug development to answer myriad questions. They can range from simple permeability screens to kinetic assessments in specialized cell systems using complex assay formats. Drug transporter assays are many and varied because numerous transporter proteins require evaluation, and study designs are usually based around the availability of an appropriate test system to study the transporter protein(s) in question. In general, experiments are conducted using polarized or transfected cell lines, hepatocytes or membrane vesicles. Each test system requires appropriate assay conditions and controls in order to generate useful data. Recent changes to the FDA in vitro DDI guidance document have emphasized the need for more considered transporter study designs to better inform in vivo expectations for drugs in development. The 2017 guidance explicitly recommends consideration of the impact of factors such as stability in the test system, non-specific binding to cells and experimental apparatus and other compound-specific characteristics in study conduct and data interpretation. Since assay designs are limited by individual test system assay needs, practically, this requires study designs to be augmented with careful monitoring and troubleshooting at assay and data interpretation stages when unexpected observations are made. In this webinar, challenges associated with some diverse compounds in what should have been straightforward in vitro transporter assays will be examined. The discussion will focus on cell-based assays and the solutions applied to problems associated with specific compound characteristics, with a progressive analysis of increasingly complex case studies. Case studies will explore the problematic observations or data, creative methods of troubleshooting applied, and how we can learn from those experiences to better understand and address surprises in future transporter studies. Request a copy of the slides or submit questions: https://www.xenotech.com/webinars/challenges-solutions-in-vitro-transporter-research

 
More Information
 
 
 

Recommended Videos

New Class of Painkiller Found in the Mud

Video

A decade-old mud sample has revealed a potential new class of painkillers that are as potent as opioids.

WATCH NOW

A "Living Drug" That Could Change the Way We Treat Cancer

Video

In a talk about a breakthrough, CAR T-cell therapy pioneer, Carl June shares how three decades of research culminated in a therapy that's eradicated cases of leukemia once thought to be incurable – and explains how it could be used to fight other types of cancer.

WATCH NOW

CAR T-cell Therapy: Reprogramming the Immune System To Treat Cancer

Video

Researchers are developing third generation CAR-T immunotherapy treatments which aim to be more effective with less side effects than previous therapies.

WATCH NOW

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE